| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | March 15, 2022 |
| Accession Number: | 0001140361-22-009060 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/9/2022 | $120.00 → $100.00 | Buy → Neutral | HC Wainwright & Co. |
| 12/21/2021 | $93.00 → $100.00 | Overweight → Neutral | Cantor Fitzgerald |
| 12/14/2021 | Market Outperform → Market Perform | JMP Securities | |
| 12/14/2021 | $112.00 → $100.00 | Outperform → Market Perform | SVB Leerink |
| 12/14/2021 | $76.00 → $100.00 | Outperform → Sector Perform | RBC Capital |
| 12/14/2021 | $98.00 → $100.00 | Outperform → Neutral | Credit Suisse |
| 12/14/2021 | $100.00 | Buy → Hold | Jefferies |
| 12/13/2021 | Buy → Hold | Needham |
15-12G - ARENA PHARMACEUTICALS INC (0001080709) (Filer)
EFFECT - ARENA PHARMACEUTICALS INC (0001080709) (Filer)
EFFECT - ARENA PHARMACEUTICALS INC (0001080709) (Filer)
HC Wainwright & Co. downgraded Arena Pharmaceuticals from Buy to Neutral and set a new price target of $100.00 from $120.00 previously
Cantor Fitzgerald downgraded Arena Pharmaceuticals from Overweight to Neutral and set a new price target of $100.00 from $93.00 previously
JMP Securities downgraded Arena Pharmaceuticals from Market Outperform to Market Perform
4 - ARENA PHARMACEUTICALS INC (0001080709) (Issuer)
4 - ARENA PHARMACEUTICALS INC (0001080709) (Issuer)
4 - ARENA PHARMACEUTICALS INC (0001080709) (Issuer)
SC 13G/A - ARENA PHARMACEUTICALS INC (0001080709) (Subject)
SC 13G/A - ARENA PHARMACEUTICALS INC (0001080709) (Subject)
SC 13G/A - ARENA PHARMACEUTICALS INC (0001080709) (Subject)
GAINERS: Nine Energy Service (NYSE:NINE) shares closed up 57.66% at $5.66 ReneSola (NYSE:SOL) shares closed up 36.36% at $8.10 GrowGeneration (NASDAQ:GRWG) shares closed up 11.07% at $8.53 Cara Therapeutics (NASDAQ:CARA) shares closed up 11.00% at $11.71 MedMen Enterprises (OTC:MMNFF) shares closed up 10.36% at $0.12 Item 9 Labs (OTC:INLB) shares closed up 8.42% at $1.03 Corbus Pharmaceuticals (NASDAQ:CRBP) shares closed up 7.06% at $0.34 Cansortium (OTC:CNTMF) shares closed up 6.36% at $0.50 Arena Pharmaceuticals (NASDAQ:ARNA) shares closed up 5.36% at $98.64 Village Farms Intl (NASDAQ:VFF) shares closed up 5.25% at $4.41 Charlottes Web Holdings (OTC:CWBHF) shares closed up 4.57% at $1.03
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) revealed Wednesday financial results for the fourth quarter and full year ended Dec. 31, 2021. Q4 Finanical HIghlights Net loss for the fourth quarter was $155.6 million compared to a net loss of $122.2 million for the same period in 2020 Basic and diluted net loss per share for the fourth quarter was $2.54 compared to basic and diluted net loss per share of $2.10 for the same period in 2020 Research and development (R&D) expenses for the fourth quarter totaled $110.3 million compared to $100.4 million in the same period in 2020. This increase was primarily driven by our advancing clinical studies, including the etrasimod Phase 3 program, as w
Arena Pharmaceuticals (NASDAQ:ARNA) reported quarterly losses of $(2.54) per share which missed the analyst consensus estimate of $(2.26) by 12.39 percent. This is a 20.95 percent decrease over losses of $(2.10) per share from the same period last year. The company reported quarterly sales of $54.00 thousand which missed the analyst consensus estimate of $660.00 thousand by 91.82 percent. This is a 45.95 percent increase over sales of $37.00 thousand the same period last year.
– Phase 3 ELEVATE UC 52 and 12 on course for Q1 2022 topline data readout Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2021. Key Program & Corporate Updates In December announced that Pfizer Inc. and Arena entered into a definitive agreement under which Pfizer has agreed to acquire Arena In November achieved target enrollment for Study A in the Phase 2/3 CULTIVATE trial for etrasimod in Crohn's disease In November the first participant was randomized in the Phase 2 trial for temanogrel in Raynaud's phenomenon secondary to systemic sclerosis Phase 3 ELEVATE program
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) will release its fourth quarter and full-year 2021 financial results and provide a corporate update on Wednesday, February 23, 2022, after the close of the U.S. financial markets. About Arena Pharmaceuticals ARENA Pharmaceuticals is a team with a singular purpose – deliver important medicines to patients. In a rapidly changing global market, we work with a sense of urgency every day to understand the needs of all our stakeholders, identify bold, sometimes disruptive, ideas to get medicines to patients, and relentlessly execute until it's done. ARENA - Care More. Act Differently. Forward-Looking Statements Certain statements in this press relea
Proposed acquisition offers potentially new, differentiated best-in-class approach to address unmet need for a broader number of patients with immuno-inflammatory diseases Expands innovative pipeline potentially enhancing growth through 2025 and beyond Transaction valued at $100 per Arena share in cash, for a total equity value of approximately $6.7 billion Pfizer to host analyst and investor call at 10am EST today with Pfizer I&I executives Pfizer Inc. (NYSE:PFE) and Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Arena, a clinical stage company developing innovative potential therapie
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced the appointment of Douglas J. Manion, M.D., F.R.C.P. (C), as Executive Vice President of Research & Development, reporting to Amit D. Munshi, President and CEO of Arena. Dr. Manion brings more than 20 years of pharmaceutical industry experience spanning three large companies, including work in all of Arena's therapeutic areas. "We are excited to have Dr. Manion join the Arena team," said Mr. Munshi. "Doug has leadership experience across all aspects of research and development, as well as extensive international experience, which will guide Arena R&D as we continue to grow and progress our portfolio." "I was attracted by the breadt
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced the appointment of Steven Schoch to the Company's Board of Directors and as Chair of the Audit Committee. Mr. Schoch brings more than 20 years of financial and operational leadership and expertise across a range of areas in biopharmaceuticals, media, and technology, including building and scaling businesses and leading innovation. "We are very pleased to have Mr. Schoch join our Board of Directors," said Garry Neil, M.D., Chair of the Board of Directors of Arena. "Steven brings both financial and strategic operational experience that will be of great benefit as Arena prepares for the next stage of growth." Mr. Schoch currently serv
SAN DIEGO--(BUSINESS WIRE)--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced changes to the Company’s Board of Directors. Garry Neil, MD, has been appointed Chair of the Board. Additionally, Nawal Ouzren has been appointed as a new Board member. “These changes in our Board leadership will help position Arena for the growth we anticipate and mark an important inflection point in our progress,” said Amit D. Munshi, President and CEO of Arena. “Garry Neil has served on the Board for the past four years, providing exceptional leadership for our scientific direction. As a physician with extensive industry experience, his insight into successfully translating scientific disco
– Phase 3 ELEVATE UC 52 and 12 on course for Q1 2022 topline data readout Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2021. Key Program & Corporate Updates In December announced that Pfizer Inc. and Arena entered into a definitive agreement under which Pfizer has agreed to acquire Arena In November achieved target enrollment for Study A in the Phase 2/3 CULTIVATE trial for etrasimod in Crohn's disease In November the first participant was randomized in the Phase 2 trial for temanogrel in Raynaud's phenomenon secondary to systemic sclerosis Phase 3 ELEVATE program
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that the Compensation Committee of its Board of Directors granted to 18 new employees 18,527 inducement restricted stock units ("RSUs"). The inducement RSUs have a grant date and vesting commencement date of February 15, 2022 and were granted as inducements material to the new employees entering employment with Arena in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement RSUs vest over four years, with 25% of the shares vesting on the first designated quarterly vesting date on or following the one-year anniversary of the vesting commencement date and the remaining 75% of the shares vesting in 12 substantially equal quarte
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) will release its fourth quarter and full-year 2021 financial results and provide a corporate update on Wednesday, February 23, 2022, after the close of the U.S. financial markets. About Arena Pharmaceuticals ARENA Pharmaceuticals is a team with a singular purpose – deliver important medicines to patients. In a rapidly changing global market, we work with a sense of urgency every day to understand the needs of all our stakeholders, identify bold, sometimes disruptive, ideas to get medicines to patients, and relentlessly execute until it's done. ARENA - Care More. Act Differently. Forward-Looking Statements Certain statements in this press relea